2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

N Ruperto;  ; P Quartier; N Wulffraat; P Woo; A Loy; R Mouy; B Bader-Meunier; B Prakken; E Noseda; C Rordorf

doi:10.1186/1546-0096-6-s1-s2

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

Pediatric Rheumatology ◽

10.1186/1546-0096-6-s1-s2 ◽

2008 ◽

Vol 6 (S1) ◽

Cited By ~ 5

Author(s):

N Ruperto ◽

◽

P Quartier ◽

N Wulffraat ◽

P Woo ◽

...

Keyword(s):

Monoclonal Antibody ◽

Juvenile Idiopathic Arthritis ◽

Phase Ii ◽

Phase Ii Trial ◽

Systemic Juvenile Idiopathic Arthritis ◽

Safety And Efficacy ◽

Efficacy Profile

Download Full-text

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Arthritis & Rheumatism ◽

10.1002/art.33342 ◽

2012 ◽

Vol 64 (2) ◽

pp. 557-567 ◽

Cited By ~ 133

Author(s):

Nicolino Ruperto ◽

Pierre Quartier ◽

Nico Wulffraat ◽

Patricia Woo ◽

Angelo Ravelli ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Ii ◽

Systemic Juvenile Idiopathic Arthritis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile—VITAL study, GEMCAD 09-02 clinical trial.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.4034 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 4034-4034 ◽

Cited By ~ 2

Author(s):

Jaime Feliu ◽

Rocio Garcia-Carbonero ◽

Jaume Capdevila ◽

Inmaculada Guasch ◽

Vicente Alonso ◽

...

Keyword(s):

Clinical Trial ◽

Squamous Cell Carcinoma ◽

Anal Canal ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Safety And Efficacy ◽

Efficacy Profile

Download Full-text

Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study)

PLoS ONE ◽

10.1371/journal.pone.0235381 ◽

2020 ◽

Vol 15 (6) ◽

pp. e0235381 ◽

Cited By ~ 2

Author(s):

Izabella Picinin Safe ◽

Marcus Vinícius Guimarães Lacerda ◽

Vitoria Silva Printes ◽

Adriana Ferreira Praia Marins ◽

Amanda Lia Rebelo Rabelo ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Hospitalized Patients ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Phase Ii

Download Full-text

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06216-5 ◽

2021 ◽

Author(s):

Zijing Wang ◽

Jiaxuan Liu ◽

Fei Ma ◽

Jiayu Wang ◽

Yang Luo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy Study ◽

Her2 Positive ◽

Safety And Efficacy ◽

Metronomic Vinorelbine

Download Full-text

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan

Pediatric Rheumatology ◽

10.1186/1546-0096-11-s2-p178 ◽

2013 ◽

Vol 11 (S2) ◽

Cited By ~ 1

Author(s):

S Yokota ◽

T Nozawa ◽

T Kanetaka ◽

K Yamazaki ◽

T Sato ◽

...

Keyword(s):

Monoclonal Antibody ◽

Juvenile Idiopathic Arthritis ◽

Interleukin 6 ◽

Systemic Juvenile Idiopathic Arthritis ◽

Interleukin 6 Receptor ◽

Receptor Monoclonal Antibody

Download Full-text

TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: Preliminary outcomes in cohort A

Annals of Oncology ◽

10.1093/annonc/mdy424.042 ◽

2018 ◽

Vol 29 ◽

pp. viii727-viii728 ◽

Cited By ~ 1

Author(s):

B.M. You ◽

P.A. Bolze ◽

J.-P. Lotz ◽

J. Massardier ◽

L. Gladieff ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase Ii ◽

Phase Ii Trial ◽

Gestational Trophoblastic Neoplasia

Download Full-text

Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3419-1 ◽

2017 ◽

Vol 80 (4) ◽

pp. 777-785 ◽

Cited By ~ 4

Author(s):

Katsuki Danno ◽

◽

Taishi Hata ◽

Koki Tamai ◽

Yujiro Fujie ◽

...

Keyword(s):

Colon Cancer ◽

Adjuvant Therapy ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Trial ◽

Japanese Patients ◽

Stage Iii ◽

Safety And Efficacy ◽

Stage Iii Colon Cancer

Download Full-text

A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL

Hematological Oncology ◽

10.1002/hon.4_2632 ◽

2019 ◽

Vol 37 ◽

pp. 557-558 ◽

Cited By ~ 1

Author(s):

M. Montillo ◽

D. Rossi ◽

E. Zucca ◽

A.M. Frustaci ◽

S. Pileri ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Open Label ◽

Safety And Efficacy

Download Full-text

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70912-7 ◽

2009 ◽

Vol 7 (2) ◽

pp. 266-267 ◽

Cited By ~ 1

Author(s):

H. Burris ◽

S. Vukelja ◽

I. Krop ◽

S. Modi ◽

B. Klencke ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Antibody Drug Conjugate ◽

Safety And Efficacy ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy

10.1158/1538-7445.am2018-ct158 ◽

2018 ◽

Cited By ~ 3

Author(s):

Roger Cohen ◽

Jérôme Fayette ◽

Marshall Posner ◽

Gautier Lefebvre ◽

Jessica Bauman ◽

...

Keyword(s):

Monoclonal Antibody ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Phase Ii Study ◽

Preliminary Assessment ◽

Safety And Efficacy ◽

Metastatic Squamous Cell Carcinoma ◽

Previously Treated

Download Full-text